BOSTON--(BUSINESS WIRE)--PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced the appointment of four company executives to its senior-most leadership team, the Business Review Committee:
- David Godwin, Senior Vice President, Global Business Development
- Michelle Graham, Senior Vice President and Chief Human Resources Officer
- Sy Pretorius, M.D., Senior Vice President and Chief Scientific Officer
- Joshua Schultz, Senior Vice President, Worldwide Head of PAREXEL Access
“PAREXEL has a history of growth, innovation and leadership that spans more than 30 years, and these leaders have played an important role in our success,” said Josef von Rickenbach, Chairman and Chief Executive Officer, PAREXEL. “Our corporate strategy is to enhance our leadership in the biopharmaceutical services industry by focusing on our core business and capturing new growth from adjacent markets. We will leverage the expertise of these senior leaders to implement our strategic objectives and further transform PAREXEL, positioning the Company for future growth.”
Mr. Godwin joined PAREXEL in 1989 and is responsible for the business development efforts for many of the Company’s services. He will continue to manage global business development initiatives.
Ms. Graham joined PAREXEL in 2015 and is responsible for the design and launch of the Company’s people strategy, talent agenda and refined Human Resources operating model. She will continue to manage the company’s Human Resources function, including talent acquisition, learning and development and organizational development as well as be responsible for the company’s Diversity and Inclusion programs.
Dr. Pretorius joined PAREXEL in 1996 and previously held leadership roles in various countries. He serves as Chief Scientific Officer and works closely with clients to design and optimize drug and device development strategies as well as find, evaluate and purchase assets. He will continue to be responsible for the overall leadership of several service offerings, including PAREXEL’s global Early Phase business, Global Medical Services, Quantitative Clinical Development and Genomic Medicine.
Mr. Schultz joined PAREXEL in 2005 and oversees the global Late Phase business, which provides clinical research services in the peri/post-approval phases, including IIIb/IV clinical trials, observational research, market access, medical communications and patient safety services. He will continue to lead PAREXEL Access.
About PAREXEL International
PAREXEL International Corporation is a leading global biopharmaceutical services company, providing a broad range of expertise-based clinical research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, and reimbursement. PAREXEL Informatics provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL has offices in 82 locations in 51 countries around the world, and had approximately 18,450 employees in the third quarter. For more information about PAREXEL International, visit www.PAREXEL.com.
PAREXEL and PAREXEL Informatics are trademarks or registered trademarks of PAREXEL International Corporation or its affiliates.
This release contains “forward-looking” statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “will,” “would,” “could,” “should,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. Such factors and others are discussed in the section entitled “Risk Factors” of the Company’s most recent Annual Report on Form 10-K and subsequent quarterly reports on Form 10-Q filed with the Securities and Exchange Commission, which “Risk Factors” discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.
